Nutra Vision

A two-track company advancing connected smart inhalers and researching natural biologics to improve lives through pulmonary delivery.

We believe people’s health can be optimized through natural remedies delivered in advanced devices. By pioneering next-gen inhaler technology, we aim to redefine pulmonary care while maintaining a patient-first commitment to researching natural biologic compounds.

We operate two focused divisions, each with substantial potential and dedicated leadership/strategy.

S-pMDI Department

(Connected Smart Inhalers)

The inhalable pharma market is large and growing, yet traditional inhalers are disconnected and inefficient. Patients struggle with adherence, personalization, and real-time monitoring; clinical trials are costly due to manual data collection and in-person monitoring.

THE PROBLEM WE’RE SOLVING

THE SOLUTION

  • Real-time data & better adherence: Connected smart inhalers automatically capture usage patterns, dosage, and inhalation technique; they can deliver reminders/feedback.

  • Lean, remote clinical trials: Automated data + remote monitoring reduce site visits and manual management, cutting costs and speeding time-to-market.

  • Personalized care: Continuous analytics enable tailored treatment plans, fewer exacerbations/hospitalizations, and improved outcomes.

  • Built to scale (and defend): Platform extends beyond respiratory indications; proprietary tech secures IP and strengthens competitive edge.

Market Opportunity (high-level stats)

Inhalable pharma projected $31.5B (2022) → ~$52.4B (2030); inhalation drug-delivery devices $20.7B (2024) → ~$34.2B (2031).

If connected smart inhalers capture 10–15% of the devices market, revenue potential is ~$2B–$5B by 2030.

Expansion beyond respiratory (e.g., diabetes, Parkinson’s) lifts addressable opportunity; related markets may reach ~$65.5B by 2034.

R&D Department

(Natural Biologics)

  • Identify natural compounds with potential therapeutic use. NUTRA deck

  • Formulate them for safe, effective delivery (integrated with our devices). NUTRA deck

  • Advance to IND & clinical studies—developing IND submissions and research protocols.

WHAT WE DO

  • Aim: Evaluate whether inhaled NC-107 reduces anxiety severity in adults with Generalized Anxiety Disorder, and assess safety & pharmacokinetics.

  • Design (core details): Adults ≥18 with moderate GAD randomized to NC-107 or placebo for 4 weeks; two puffs, twice daily; scheduled assessments, vitals, labs, and blood draws for PK.

  • Potential benefits: Symptom reduction; contribution to developing a new GAD treatment option.

  • Key risks (high-level): Unknown drug side effects; routine risks from blood draws.

Initial Clinical Program (NC-107 for GAD)

Why This Two-Division Model?

Hardware + data platform unlock adherence, personalization, and research efficiency; biologics research supplies differentiated formulations that our device can deliver—creating a defensible ecosystem and multi-modal growth path.

NC-107 is an investigational product not approved for sale; safety and efficacy have not been established.

Our Go To Market Strategy

Market Segmentation & Target Audience

Primary Customers:

  • Pharmaceutical Manufacturers: Looking to differentiate generic inhalation therapies.

  • Respiratory Drug License Holders: Seeking device/formulation alignment for ANDAs or NDAs.

  • Digital Health Startups/Chronic Care Platforms: In need of smart hardware integration for remote patient monitoring (RPM).

  • Health Plans & Payers: Interested in risk-based models and adherence-focused tools.

Geographic Focus:

  • Phase 1: U.S., U.K., EU (established pMDI markets with high regulatory clarity)

  • Phase 2: LATAM, Middle East, India (price-sensitive, high-growth respiratory markets)

Positioning & Value Propositions

White Labeling Strategy

What We Offer:

  • Fully customizable device housing, colors, logos

  • App rebranding (for Optimist™) with API access for EHR/RPM integration

  • Regulatory-ready documentation (FDA/EMA pathways)

  • Optional device + drug pairing consultation for co-packaging

White Label Support Package:

  • Co-branded demo kits

  • Private-label app skinning (Optimist™)

  • Instructional materials + regulatory onboarding

  • Tiered licensing or per-unit model

Sales & Distribution Channels

Direct Outreach:

  Partner sales team targeting decision-makers at:

•Respiratory-focused pharma firms

•Digital therapeutics teams

•Clinical operations in payer organizations

Industry Events:

•ATS, DTx West, CPhI, BIO International
(Live white label demos, pitch decks, sample units)

Strategic Partnerships:

Collaborate with:

•Contract Manufacturing Orgs (CMOs)

•Drug delivery consultancies

•EHR integration platforms (for Optimist)

Partner With Us

We work with health systems, research sites, and strategic partners to advance connected inhaler solutions and natural biologics.

  • • Health systems and provider groups

    • Research sites / CROs / study sponsors

    • Device OEMs, distributors & pharmacies

    • Universities / labs

    • Strategic investors & channel partners

    • Real-time adherence and inhalation-technique data

    • Remote monitoring to streamline studies and care pathways

    • Device + formulation roadmap with clear milestones

    • Data governance and privacy safeguards (HIPAA-aligned language if appropriate)

    • Dedicated point of contact and defined success metrics